R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.
about
Speech in ALS: Longitudinal Changes in Lips and Jaw Movements and Vowel AcousticsThe abolishment of anesthesia-induced cognitive impairment by timely protection of mitochondria in the developing rat brain: the importance of free oxygen radicals and mitochondrial integrityNew Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders.Catalytic antioxidants and neurodegenerationPotential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.Emerging drugs for amyotrophic lateral sclerosis.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency.Current and emerging treatments for amyotrophic lateral sclerosis.Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease.Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
P2860
Q30378560-6F8BB414-14C7-4A32-958B-B8173C818A39Q30422273-1F471F05-4756-4534-AEB0-B3EEAC3F130DQ33783000-6708D27F-2597-4F86-9FA9-DBF0DF083E5AQ34104938-0498C35E-C961-46C1-A779-E2D535C77D5BQ34276055-CA725BC5-A2E8-4384-BBBD-BBF5C92009F1Q35958359-9EB8BFE7-2D62-4398-A803-7E25A2EC828AQ36202825-2F765949-7AB6-40E2-BFBD-BB5792FA52FEQ37909351-42C6501C-2A06-4857-B984-E57EF3833A54Q38573829-12AD0AF2-9FF1-49AF-993D-E43C138FBF49Q42153700-6F7302A2-8E66-4573-9FA6-7DDB183D37F3Q42685032-9912EC29-DD5D-45D3-83E1-D6C90A40EDABQ45023714-0E901056-03F9-4872-A325-4C7946E70B26Q51536742-B6157550-B8AF-48DD-89DA-A38207392A34Q56773744-B08E10C0-A2C0-465B-8985-C63D1B9AEDDF
P2860
R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@ast
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@en
type
label
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@ast
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@en
altLabel
R+ pramipexole as a mitochondr ...... ial early phase studies in ALS
@en
prefLabel
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@ast
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@en
P2093
P2860
P1476
R+ pramipexole as a mitochondr ...... al early phase studies in ALS.
@en
P2093
David Lacomis
Gary L Pattee
James P Bennett
Kathleen A Ware
Kristen E Keller
Kylyana S Larriviere
Lawrence H Phillips
Mark A Conaway
Nina J Solenski
P2860
P356
10.1080/17482960701791234
P407
P577
2008-02-01T00:00:00Z